{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:02:40Z","timestamp":1782025360418,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T00:00:00Z","timestamp":1510704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Z01-SC-004020"],"award-info":[{"award-number":["Z01-SC-004020"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00262-017-2084-x","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T11:16:48Z","timestamp":1510744608000},"page":"1863-1869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Cancer vaccine strategies: translation from mice to human clinical trials"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-3194","authenticated-orcid":false,"given":"Jay A.","family":"Berzofsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Terabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane B.","family":"Trepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren V.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,15]]},"reference":[{"key":"2084_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev.iy.11.040193.002155","volume":"11","author":"RN Germain","year":"1993","unstructured":"Germain RN, Margulies DH (1993) The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403\u2013450","journal-title":"Annu Rev Immunol"},{"key":"2084_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.immunol.16.1.323","volume":"16","author":"E Pamer","year":"1998","unstructured":"Pamer E, Cresswell P (1998) Mechanisms of MHC class I\u2013restricted antigen processing. Annu Rev Immunol 16:323\u2013358","journal-title":"Annu Rev Immunol"},{"key":"2084_CR3","doi-asserted-by":"publisher","first-page":"8372","DOI":"10.1073\/pnas.1533209100","volume":"100","author":"GQ Phan","year":"2003","unstructured":"Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372\u20138377","journal-title":"Proc Natl Acad Sci USA"},{"key":"2084_CR4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126\u2013129","journal-title":"Science"},{"key":"2084_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1479-5876-9-214","volume":"9","author":"BA Fox","year":"2011","unstructured":"Fox BA, Schendel DJ, Butterfield LH et al (2011) Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214. doi:\n                    10.1186\/1479-5876-9-214","journal-title":"J Transl Med"},{"key":"2084_CR6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443\u20132454. doi:\n                    10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"key":"2084_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/515496a","volume":"515","author":"JD Wolchok","year":"2014","unstructured":"Wolchok JD, Chan TA (2014) Cancer: antitumour immunity gets a boost. Nature 515:496\u2013498. doi:\n                    10.1038\/515496a","journal-title":"Nature"},{"key":"2084_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56\u201361. doi:\n                    10.1126\/science.aaa8172","journal-title":"Science"},{"key":"2084_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411\u2013422. doi:\n                    10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"key":"2084_CR10","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17:3520\u20133526. doi:\n                    10.1158\/1078-0432.CCR-10-3126","journal-title":"Clin Cancer Res"},{"key":"2084_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri1150","volume":"3","author":"OJ Finn","year":"2003","unstructured":"Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630\u2013641","journal-title":"Nat Rev Immunol"},{"key":"2084_CR12","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"OJ Finn","year":"2008","unstructured":"Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704\u20132715. doi:\n                    10.1056\/NEJMra072739","journal-title":"N Engl J Med"},{"key":"2084_CR13","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1172\/JCI21926","volume":"113","author":"JA Berzofsky","year":"2004","unstructured":"Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC (2004) Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Investig 113:1515\u20131525","journal-title":"J Clin Investig"},{"key":"2084_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1586\/14760584.2013.836906","volume":"12","author":"JA Berzofsky","year":"2013","unstructured":"Berzofsky JA, Wood LV, Terabe M (2013) Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. Expert Rev Vaccines 12:1115\u20131118. doi:\n                    10.1586\/14760584.2013.836906","journal-title":"Expert Rev Vaccines"},{"key":"2084_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1364322","author":"ME Gatti-Mays","year":"2017","unstructured":"Gatti-Mays ME, Redman JM, Collins JM, Bilusic M (2017) Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother. doi:\n                    10.1080\/21645515.2017.1364322","journal-title":"Hum Vaccin Immunother"},{"key":"2084_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.194.6.823","volume":"194","author":"RPM Sutmuller","year":"2001","unstructured":"Sutmuller RPM, Van Duivenvoorde LM, Van Elsas A, Schumacher TNM, Wildenberg ME, Allison JP, Toes REM, Offringa R, Melief CJM (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative cytotoxic T lymphocyte responses. J Exp Med 194:823\u2013832","journal-title":"J Exp Med"},{"key":"2084_CR17","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1158\/1078-0432.CCR-08-1266","volume":"14","author":"MA Cheever","year":"2008","unstructured":"Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A, Grad O, Nelson WG (2008) Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res 14:5692\u20135699. doi:\n                    10.1158\/1078-0432.CCR-08-1266","journal-title":"Clin Cancer Res"},{"key":"2084_CR18","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.1158\/1078-0432.CCR-09-1066","volume":"15","author":"M Terabe","year":"2009","unstructured":"Terabe M, Ambrosino E, Takaku S, O\u2019Konek JJ, Venzon D, Lonning S, McPherson JM, Berzofsky JA (2009) Synergistic enhancement of CD8\u00a0+\u00a0T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 15:6560\u20136569. doi:\n                    10.1158\/1078-0432.CCR-09-1066","journal-title":"Clin Cancer Res"},{"key":"2084_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1308616","author":"M Terabe","year":"2017","unstructured":"Terabe M, Robertson FC, Clark K, De Ravin E, Bloom A, Venzon D, Kato S, Mirza A, Berzofsky JA (2017) Blockade of only TGF-\u03b2 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. OncoImmunology. doi:\n                    10.1080\/2162402X.2017.1308616","journal-title":"OncoImmunology"},{"key":"2084_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le DT, Lutz E, Uram JN et al (2013) Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36:382\u2013389. doi:\n                    10.1097\/CJI.0b013e31829fb7a2","journal-title":"J Immunother"},{"key":"2084_CR21","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1158\/1078-0432.CCR-13-2424","volume":"19","author":"DT Le","year":"2013","unstructured":"Le DT, Jaffee EM (2013) Harnessing immune responses in the tumor microenvironment: all signals needed. Clin Cancer Res 19:6061\u20136063. doi:\n                    10.1158\/1078-0432.CCR-13-2424","journal-title":"Clin Cancer Res"},{"key":"2084_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1202114","author":"TJ Vreeland","year":"2016","unstructured":"Vreeland TJ, Clifton GT, Herbert GS, Hale DF, Jackson DO, Berry JS, Peoples GE (2016) Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. Expert Rev Clin Immunol. doi:\n                    10.1080\/1744666X.2016.1202114","journal-title":"Expert Rev Clin Immunol"},{"key":"2084_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1053\/j.seminoncol.2016.06.008","volume":"43","author":"RE Parchment","year":"2016","unstructured":"Parchment RE, Voth AR, Doroshow JH, Berzofsky JA (2016) Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Semin Oncol 43:501\u2013513. doi:\n                    10.1053\/j.seminoncol.2016.06.008","journal-title":"Semin Oncol"},{"key":"2084_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1749-6632.1993.tb44014.x","volume":"690","author":"JA Berzofsky","year":"1993","unstructured":"Berzofsky JA (1993) Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann NY Acad Sci 690:256\u2013264","journal-title":"Ann NY Acad Sci"},{"key":"2084_CR25","doi-asserted-by":"publisher","first-page":"10856","DOI":"10.1073\/pnas.94.20.10856","volume":"94","author":"JD Ahlers","year":"1997","unstructured":"Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA (1997) Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 94:10856\u201310861","journal-title":"Proc Natl Acad Sci USA"},{"key":"2084_CR26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1172\/JCI3714","volume":"102","author":"P Sarobe","year":"1998","unstructured":"Sarobe P, Pendleton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM, Berzofsky JA (1998) Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Investig 102:1239\u20131248","journal-title":"J Clin Investig"},{"key":"2084_CR27","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1172\/JCI200113463","volume":"108","author":"JD Ahlers","year":"2001","unstructured":"Ahlers JD, Belyakov IM, Thomas EK, Berzofsky JA (2001) High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J. Clin. Investig 108:1677\u20131685","journal-title":"J. Clin. Investig"},{"key":"2084_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/35105075","volume":"1","author":"JA Berzofsky","year":"2001","unstructured":"Berzofsky JA, Ahlers JD, Belyakov IM (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1:209\u2013219","journal-title":"Nat Rev Immunol"},{"key":"2084_CR29","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.4049\/jimmunol.171.5.2548","volume":"171","author":"T Okazaki","year":"2003","unstructured":"Okazaki T, Pendleton DC, Lemonnier F, Berzofsky JA (2003) Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J. Immunol 171:2548\u20132555","journal-title":"J. Immunol"},{"key":"2084_CR30","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.4049\/jimmunol.176.6.3753","volume":"176","author":"T Okazaki","year":"2006","unstructured":"Okazaki T, Pendleton CD, Sarobe P, Thomas EK, Harro C, Schwartz D, Iyengar S, Berzofsky JA (2006) Epitope-enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J Immunol 176:3753\u20133759","journal-title":"J Immunol"},{"key":"2084_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1600-065X.1987.tb00518.x","volume":"98","author":"JA Berzofsky","year":"1987","unstructured":"Berzofsky JA, Cease KB, Cornette JL, Spouge JL, Margalit H, Berkower IJ, Good MF, Miller LH, DeLisi C (1987) Protein antigenic structures recognized by T cells: potential applications to vaccine design. Immunol Rev 98:9\u201352","journal-title":"Immunol Rev"},{"key":"2084_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/BF00172063","volume":"41","author":"HG Rammensee","year":"1995","unstructured":"Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178\u2013228","journal-title":"Immunogenetics"},{"key":"2084_CR33","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/0092-8674(93)90472-3","volume":"74","author":"J Ruppert","year":"1993","unstructured":"Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929\u2013937","journal-title":"Cell"},{"key":"2084_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1089\/aid.1996.12.593","volume":"12","author":"CGP Roberts","year":"1996","unstructured":"Roberts CGP, Meister GE, Jesdale BT, Lieberman J, Berzofsky JA, DeGroot AS (1996) Prediction of HIV peptide epitopes by a novel algorithm. AIDS Res Hum Retroviruses 12:593\u2013610","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2084_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1006\/jmbi.1998.1982","volume":"281","author":"C Zhang","year":"1998","unstructured":"Zhang C, Anderson A, DeLisi C (1998) Structural principles that govern the peptide-binding motifs of class I MHC molecules. J Mol Biol 281:929\u2013947","journal-title":"J Mol Biol"},{"key":"2084_CR36","doi-asserted-by":"publisher","first-page":"9437","DOI":"10.1073\/pnas.160270597","volume":"97","author":"CD Wolfgang","year":"2000","unstructured":"Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I (2000) TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci USA 97:9437\u20139442","journal-title":"Proc Natl Acad Sci USA"},{"key":"2084_CR37","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/0008-5472.CAN-03-2183","volume":"64","author":"S Oh","year":"2004","unstructured":"Oh S, Terabe M, Pendleton CD et al (2004) Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Can Res 64:2610\u20132618","journal-title":"Can Res"},{"key":"2084_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1197459","author":"LV Wood","year":"2016","unstructured":"Wood LV, Fojo A, Roberson BD et al (2016) TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. Oncolmmunology. doi:\n                    10.1080\/2162402X.2016.1197459","journal-title":"Oncolmmunology"},{"key":"2084_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433\u2013439. doi:\n                    10.1001\/jama.294.4.433","journal-title":"JAMA"},{"key":"2084_CR40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591\u20131597","journal-title":"JAMA"},{"key":"2084_CR41","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1200\/JCO.2006.08.0572","volume":"25","author":"SJ Freedland","year":"2007","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2007) Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25:1765\u20131771. doi:\n                    10.1200\/JCO.2006.08.0572","journal-title":"J Clin Oncol"},{"key":"2084_CR42","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/cncr.26437","volume":"118","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA (2012) Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials. Cancer 118:1533\u20131542. doi:\n                    10.1002\/cncr.26437","journal-title":"Cancer"},{"key":"2084_CR43","doi-asserted-by":"publisher","first-page":"8669","DOI":"10.1158\/1078-0432.CCR-05-1668","volume":"11","author":"SF Slovin","year":"2005","unstructured":"Slovin SF, Wilton AS, Heller G, Scher HI (2005) Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11:8669\u20138673. doi:\n                    10.1158\/1078-0432.CCR-05-1668","journal-title":"Clin Cancer Res"},{"key":"2084_CR44","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijrobp.2005.03.008","volume":"63","author":"AK Lee","year":"2005","unstructured":"Lee AK, Levy LB, Cheung R, Kuban D (2005) Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63:456\u2013462. doi:\n                    10.1016\/j.ijrobp.2005.03.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2084_CR45","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1158\/1078-0432.CCR-10-1762","volume":"17","author":"WD Stein","year":"2011","unstructured":"Stein WD, Gulley JL, Schlom J et al (2011) Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907\u2013917. doi:\n                    10.1158\/1078-0432.CCR-10-1762","journal-title":"Clin Cancer Res"},{"key":"2084_CR46","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-16-2199","volume":"23","author":"L Castiello","year":"2017","unstructured":"Castiello L, Sabatino M, Ren J, Terabe M, Khuu H, Wood LV, Berzofsky JA, Stroncek DF (2017) Expression of CD14, IL10, and tolerogenic signature in dendritic cells inversely correlate with clinical and immunologic response to TARP vaccination in prostate cancer patients. Clin Cancer Res 23:3352\u20133364. doi:\n                    10.1158\/1078-0432.CCR-16-2199","journal-title":"Clin Cancer Res"},{"key":"2084_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1053\/sonc.2002.34056","volume":"29","author":"TM Foy","year":"2002","unstructured":"Foy TM, Fanger GR, Hand S, Gerard C, Bruck C, Cheever MA (2002) Designing HER2 vaccines. Semin Oncol 29:53\u201361","journal-title":"Semin Oncol"},{"key":"2084_CR48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1172\/JCI11752","volume":"107","author":"KL Knutson","year":"2001","unstructured":"Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2\/neu helper peptide vaccine generates HER- 2\/neu CD8 T-cell immunity in cancer patients. J Clin Investig 107:477\u2013484","journal-title":"J Clin Investig"},{"key":"2084_CR49","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/cncr.23772","volume":"113","author":"JP Holmes","year":"2008","unstructured":"Holmes JP, Gates JD, Benavides LC et al (2008) Optimal dose and schedule of an HER-2\/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 113:1666\u20131675","journal-title":"Cancer"},{"key":"2084_CR50","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-03-3442","volume":"64","author":"Y Sakai","year":"2004","unstructured":"Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC (2004) Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Can Res 64:8022\u20138028","journal-title":"Can Res"},{"key":"2084_CR51","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.4049\/jimmunol.174.7.4228","volume":"174","author":"JM Park","year":"2005","unstructured":"Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA (2005) Early Role of CD4\u00a0+\u00a0Th1 cells and antibodies in HER-2 adenovirus-vaccine protection against autochthonous mammary carcinomas. J Immunol 174:4228\u20134236","journal-title":"J Immunol"},{"key":"2084_CR52","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1158\/0008-5472.CAN-07-5688","volume":"68","author":"JM Park","year":"2008","unstructured":"Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC, Berzofsky JA (2008) Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2\/neu vaccine. Cancer Res 68:1979\u20131987","journal-title":"Cancer Res"},{"key":"2084_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443\u2013446","journal-title":"Nat Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2084-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T10:45:02Z","timestamp":1589625902000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2084-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,15]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2084"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2084-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,15]]},"assertion":[{"value":"25 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal protocols were approved by the NCI Animal Care and Use Committee accredited by the AAALAC and followed all the AAALAC regulations for animal care and use. The human protocols (NCI 09-C-0139 and 13-C-0016) were all approved by the NCI-NIH Institutional Review Board and the US Food and Drug Administration, and met all the United States ethical standards required for human studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"After appropriate explanation provided by the protocol principal investigator, all human subjects signed informed consent documents approved by the NCI-NIH Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}